I typically reserve checkpoint inhibitors as a last resort treatment option in patients with EGFR mutant non-small cell lung cancer. I have used the IMpower150 regimen on several occasions, though we now have multiple datasets confirming the generally minimal benefit from immunotherapy for patients ...